Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders

OBJECTIVE: Disease-modifying drugs (DMDs) may alter the immune status and thus increase the susceptibility to coronavirus disease 2019 (COVID-19) in patients with MS or neuromyelitis optica spectrum disorders (NMOSD). However, evidence supporting this notion is currently lacking. In this study, we c...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Moli, Qiu, Wei, Bu, Bitao, Xu, Yan, Yang, Huan, Huang, Dehui, Lau, Alexander Y., Guo, Jun, Zhang, Mei-Ni, Zhang, Xinghu, Yang, Chun-Sheng, Chen, Jingshan, Zheng, Pei, Liu, Qiang, Zhang, Chao, Shi, Fu-Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286663/
https://www.ncbi.nlm.nih.gov/pubmed/32503092
http://dx.doi.org/10.1212/NXI.0000000000000787

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286663/
https://www.ncbi.nlm.nih.gov/pubmed/32503092
http://dx.doi.org/10.1212/NXI.0000000000000787

Ejemplares similares